 Akero Therapeutics, Inc. Nasdaq: AKRO, a cardio-metabolic non-alcoholic steatohepatitis NASH company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported second quarter financial results for the period ending June 30, 2020. 